

Revance Therapeutics, Inc.  
 Form 4  
 February 11, 2014

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**GARDNER PHYLLIS**

(Last) (First) (Middle)

C/O ESSEX WOODLANDS  
 HEALTH VENTURES, 335  
 BRYANT STREET, THIRD  
 FLOOR

(Street)

PALO ALTO, CA 94301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol

Revance Therapeutics, Inc. [RVNC]

3. Date of Earliest Transaction (Month/Day/Year)

02/11/2014

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/11/2014		C		402,934 (1)	A	(2)	402,934	I	by Essex Woodlands Health Ventures Fund V, L.P. (3)
Common Stock	02/11/2014		C		41,312 (4)	A	(4)	444,246	I	by Essex Woodlands Health Ventures

Edgar Filing: Revance Therapeutics, Inc. - Form 4

Common Stock	02/11/2014	X	12,839 <u>(5)</u>	A	<u>(5)</u>	457,085	I	Fund V, L.P. <u>(3)</u>  by Essex Woodlands Health Ventures Fund V, L.P. <u>(3)</u>
--------------	------------	---	----------------------	---	------------	---------	---	---

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series E-1 Convertible Preferred Stock	<u>(2)</u>	02/11/2014		C	124,558	<u>(2)</u> <u>(2)</u>	Common Stock	124,558	
Series E-2 Convertible Preferred Stock	<u>(2)</u>	02/11/2014		C	115,337	<u>(2)</u> <u>(2)</u>	Common Stock	115,337	
Series E-3 Convertible Preferred Stock	<u>(2)</u>	02/11/2014		C	115,787	<u>(2)</u> <u>(2)</u>	Common Stock	115,787	
Series E-4 Convertible Preferred	<u>(2)</u>	02/11/2014		C	47,252	<u>(2)</u> <u>(2)</u>	Common Stock	47,252	



## Edgar Filing: Revance Therapeutics, Inc. - Form 4

(6) Automatically net exercised into shares of the Issuer's Common Stock at an exercise price of \$0.15 per share.

Includes certain warrant to purchase capital stock of the Issuer issued on December 6, 2013 by the Issuer pursuant to a Note and Warrant

(7) Purchase Agreement dated October 8, 2013, as amended. The warrant shares were automatically net exercised into Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a per share exercise price of \$0.15 per share on a post-split basis.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.